The World Health Organization has released updated guidelines focused on tuberculosis management.

Module 3 provides essential guidance on diagnosing TB and drug resistance. New recommendations include concurrent testing across all age groups and updated diagnostic technologies, ensuring a structured approach for effective TB detection.

Module 4 focuses on managing TB treatment effectively. With rigorous evidence-based recommendations, it integrates new practices for drug-susceptible and drug-resistant TB, enhancing patient care and support strategies.

Adults with drug-susceptible pulmonary TB can now be treated in just four months. This development makes TB therapy more manageable, allowing for enhanced adherence and better health outcomes for patients.

For drug-resistant TB, the new all-oral regimens dramatically cut treatment time from 15-20 months to just six months. These innovations represent a significant improvement in patient comfort and adherence.

WHO is facilitating the integration of these guidelines through operational handbooks and regional workshops. Collaborative efforts with major health organizations emphasize the importance of these updates in national TB programs.

Despite progress, challenges like testing infrastructure and treatment adherence persist. Ongoing research and support from WHO and partners are crucial for enhancing global TB elimination efforts.